Biosimilars Market Share, Size, Analysis and Forecast

Technavio Announces the Publication of its Research Report – Global Biosimilars Market 2016-2020

Technavio recognizes the following companies as the key players in the global biosimilars market: Sandoz, Hospira, Teva Pharmaceuticals, STADA, Biocon, Celltrion, Dr. Reddy's,

Other Prominent Vendors in the market are: 3SBio, Accord Healthcare, AET Biotech, Allergan, Alvartis Pharma, Amega Biotech, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Bharat Serums, Bio Sidus, Biogen, Bionovis, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Boston Oncology, Cipla, Coherus Biosciences, Daiichi Sankyo, Emcure Pharmaceuticals, Gedeon Richter, GeneScience Pharmaceuticals, GSK, Hetero Drugs, iBio, Intas Pharmaceuticals, JCR Pharmaceuticals, LG Lifesciences, Lonza, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Mylan, Mylan, Mylan, Pfenex, Pfenex, Ranbaxy Laboratories, Roche Holding, Samsung Biologics, Sanofi, Synthon, Wockhardt, and Wockhardt.

Browse full report with TOC@

Commenting on the report, an analyst from Technavio’s team said: “Emergence of biosimilars will be a key trend for market growth. The sales of biologics are expected to decline during the forecast period, owing to the increased sales of their biosimilar versions, which cost lesser and are almost similar to their originator biologic compounds. For instance, epoetin alfa BS injection by JCR Pharmaceuticals and Kissei Pharmaceutical is a biosimilar form of epoetin alfa that was launched in the market in May 2010. Similarly, the US FDA approved Inflectra in April 2016 to treat autoimmune and inflammatory diseases.”

According to the report, Reimbursement benefits for biosimilars will be a key driver for market growth. Lack of cost-effectiveness impeding the coverage of drugs results in variations in the reimbursement status of drugs from region to region. The Medicare and Medicaid...